Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population

Sagara, Hironori; Barbier, Nathalie; Ishii, Tsuyoshi; Yoshisue, Hajime; Nikolaev, Ivan; Hosoe, Motoi; Gon, Yasuhiro

doi:10.1136/bmjresp-2020-000856

Cited by 7 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A review of randomized controlled trials evaluating efficacy and safety of add‐on tiotropium in children and adolescents also supports the recently expanded indication by regulatory authorities in patients 6 years or older [51]. The efficacy and safety of fixed‐dose combination (FDC) triple therapy (ICS/LABA/LAMA) for GINA Steps 4 and 5 patients has been demonstrated by the recent clinical trials [52–60]. Therefore, the GINA guidelines have expanded the scope of asthma treatment since 2021 to include other LAMA molecules like glycopyrronium, umeclidinium, and FDC triple therapy for patients with asthma [1, 41, 54, 61, 62].…”

Section: Barriers To Achieving Optimum Asthma Controlmentioning

confidence: 97%

Burden and unmet needs in asthma care in the Asia‐Pacific region

Wadhawan¹,

Muthukumaru

Loh

2022

Public Health Challenges

View full text Add to dashboard Cite

Asthma is a chronic respiratory disease with increasing global prevalence. It affects approximately 300 million people globally and more than a third of these patients have uncontrolled asthma. The burden of poorly controlled asthma is considerable both for the individuals and the society. The World Health Organization (WHO) estimates that, 455,000 people died from asthma worldwide in 2019, the majority in low and low‐middle‐income countries. This article highlights the unmet needs and burden of asthma in the Asia‐Pacific region where many patients have poorly controlled asthma despite advances in asthma care and treatment. A mismatch between patients’ (and physicians’) perception of asthma control and optimal asthma control as defined by the Global Initiative for Asthma (GINA) is a challenge in the real‐life management of many patients. Consequently, treatment adherence and optimization are affected. In many of these aspects, patients with asthma in the Asia‐Pacific region are comparatively worse than those from Europe and North America. In future, cooperation of all stakeholders is needed in improving awareness, education, and goal‐directed management of asthma with meaningful improvement in quality of life. This article draws attention to some of the important gaps in asthma management in the Asia‐Pacific region and suggests some measures to address these unmet needs.

show abstract

Section: Barriers To Achieving Optimum Asthma Controlmentioning

confidence: 97%

Burden and unmet needs in asthma care in the Asia‐Pacific region

Wadhawan¹,

Muthukumaru

Loh

2022

Public Health Challenges

View full text Add to dashboard Cite

show abstract

“…[ 151 ] Further data showed that this SITT improved lung function, reduced asthma exacerbations, and provided comparable asthma control to the ICS/LABA combination. [ 157 ] SITT with a lower dose of mometasone furoate (mometasone furoate/indacaterol/glycopyrronium 80/150/50 μg) could be considered as an option for a patient with lower biomarkers for type 2 airway inflammation (Evidence D). It can also be considered for step down once control is achieved upon using higher dose SITT.…”

Section: Section 6: Pharmacological Management In Adults and Adolescentsmentioning

confidence: 99%

“…Available triple therapy combinations for asthma management are fluticasone furoate/umeclidinium/vilanterol (Trelegy ® ), Beclomethasone dipropionate/Formoterol/glycopyrronium (Trimbow ® ), and mometasone furoate/glycopyrronium/indacaterol (Enerzair Breezhaler ® ). [ 151 155 156 157 158 ] In a systematic review and meta-analysis, among children (aged 6–18 years) and adults with moderate to severe asthma, triple therapy, compared with dual therapy of medium to high dose ICS/LABA, was significantly associated with 17% fewer severe asthma exacerbations and modest improvements in asthma control without significant differences in quality of life or mortality. [ 503 ] In a meta-analysis of Phase III studies, triple combination therapies with a high-dose ICS/LABA/LAMA administered were more effective than medium-dose FDC against moderate to severe exacerbation and increasing trough FEV 1 .…”

Section: Single Inhaler Triple Therapy With Inhaled Corticosteroids L...mentioning

confidence: 99%

The Saudi initiative for asthma – 2024 update: Guidelines for the diagnosis and management of asthma in adults and children

Al-Moamary,

Alhaider,

Allehebi

et al. 2023

Annals of Thoracic Medicine

View full text Add to dashboard Cite

The Saudi Initiative for Asthma 2024 (SINA-2024) is the sixth version of asthma guidelines for the diagnosis and management of asthma for adults and children that was developed by the SINA group, a subsidiary of the Saudi Thoracic Society. The main objective of the SINA is to have guidelines that are up-to-date, simple to understand, and easy to use by healthcare workers dealing with asthma patients. To facilitate achieving the goals of asthma management, the SINA Panel approach is mainly based on the assessment of symptom control and risk for both adults and children. The approach to asthma management is aligned for age groups: adults, adolescents, children aged 5–12 years, and children aged <5 years. SINA guidelines have focused more on personalized approaches reflecting a better understanding of disease heterogeneity with the integration of recommendations related to biologic agents, evidence-based updates on treatment, and the role of immunotherapy in management. The medication appendix has also been updated with the addition of recent evidence, new indications for existing medication, and new medications. The guidelines are constructed based on the available evidence, local literature, and the current situation at national and regional levels. There is also an emphasis on patient–doctor partnership in the management that also includes a self-management plan.

show abstract

“…1 A triple therapy (inhaled corticosteroid [ICS]/long-acting beta-2 agonist [LABA]/long-acting muscarinic antagonist [LAMA]) is effective for managing moderate-to-severe asthma. [2][3][4][5][6] However, triple therapy is recommended as a second-line treatment for patients with uncontrolled asthma using ICS/LABA dual therapy. 1 The GINA reports also recommend that ICS/LABA dual therapy be selected in patients with uncontrolled asthma using low-dose ICS monotherapy.…”

Section: Introductionmentioning

confidence: 99%

The Efficacy and Safety of First-Line Single-Inhaler Triple versus Dual Therapy in Controller-Naïve and Symptomatic Adults with Asthma: A Preliminary Retrospective Cohort Study

Fujiki¹,

Kawayama²,

Furukawa³

et al. 2023

JAA

View full text Add to dashboard Cite

Purpose The efficacy and safety of first-line triple and dual therapy remain unclear because the stepwise strategy is a worldwide standard in controller-naïve asthma. A preliminary retrospective cohort study was conducted to investigate the efficacy and safety of first-line triple and dual therapy for managing controller-naïve and symptomatic adult patients with asthma. Patients and Methods Patients with asthma who received first-line single-inhaler triple therapy (SITT) or dual therapy (SIDT) for at least 8 weeks were selected between December 1, 2020, and May 31, 2021, in Fujiki Medical and Surgical Clinic, Miyazaki, Japan. Data on daytime and nighttime visual analog scale (VAS) scores, lung function tests, fractional exhaled nitrogen oxide (F E NO), and adverse events were compared between SITT and SIDT pre- and post-treatment. Results The SITT significantly improved the nighttime, but not daytime, VAS scores better than the SIDT 2 weeks post-treatment ( P = 0.0026), whereas SITT and SIDT significantly improved daytime and nighttime VAS scores after treatment compared to baseline. Both therapies also significantly improved lung functions and F E NO post-treatment. The proportion of patients achieving complete control in the nighttime VAS scores after SITT was significantly higher than that four ( P = 0.0186) and 8 weeks ( P = 0.0061) after SIDT. Only patients with SITT experienced dry mouth. Conclusion Our study demonstrated that first-line SITT and SIDT were effective, and SITT improved disease control faster than SIDT in controller-naïve and symptomatic adult patients with asthma. The first-line SITT may contribute to faster and better control levels in symptomatic patients with asthma.

show abstract

Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population

Cited by 7 publications

References 23 publications

Burden and unmet needs in asthma care in the Asia‐Pacific region

Burden and unmet needs in asthma care in the Asia‐Pacific region

The Saudi initiative for asthma – 2024 update: Guidelines for the diagnosis and management of asthma in adults and children

The Efficacy and Safety of First-Line Single-Inhaler Triple versus Dual Therapy in Controller-Naïve and Symptomatic Adults with Asthma: A Preliminary Retrospective Cohort Study

Contact Info

Product

Resources

About